HOME >> MEDICINE >> NEWS
Studies indicate medication can be an effective therapy for smoking cessation

The drug varenicline shows effectiveness in helping smokers quit and abstain from smoking when compared to placebo and the smoking cessation medication bupropion, according to three studies in the July 5 issue of JAMA.

Although nearly 41 percent of smokers try to quit smoking each year, relapse is common, and only about 10 percent achieve and maintain abstinence. The negative effects of nicotine withdrawal account, in part, for low success rates, according to background information in the article. Approved pharmacotherapies to treat nicotine dependence (e.g., nicotine replacement therapy and bupropion) have had important, but moderate efficacy, with reported rates of quitting generally twice those of placebo. Additional and more effective therapies are needed.

David Gonzales, Ph.D., of Oregon Health & Science University, Portland, and colleagues with the Varenicline Phase 3 Study Group evaluated the efficacy of varenicline compared with placebo and sustained-release (SR) bupropion in generally healthy adult smokers. Varenicline is a non-nicotine drug that is thought to be beneficial for smoking cessation by stimulating the release of the chemical dopamine in the brain to reduce craving and withdrawal while simultaneously blocking the reinforcing effects of smoked nicotine. Most other smoking cessation pharmacotherapies are nicotine replacement products.

Participants in the study were 1,025 smokers (10 cigarettes or more per day) with fewer than 3 months of smoking abstinence in the past year. The randomized, double-blind, phase 3 clinical trial was conducted at 19 U.S. centers from June 2003 to April 2005. Participants were randomly assigned to receive brief counseling plus either varenicline twice per day (n = 352), bupropion SR twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up.

The carbon monoxideconfirmed 4-week continuous abstinence rate for weeks 9 th
'"/>

Contact: Tamara Hargens
503-494-8231
JAMA and Archives Journals
4-Jul-2006


Page: 1 2 3 4 5 6 7

Related medicine news :

1. Studies show antidepressants not linked to birth defects
2. Studies show role of age, gender, race and weight on cancer risk and treatment
3. Studies suggest investigational agent reduces disease activity in MS
4. Studies highlight advances in diagnosis, medical therapy
5. Studies highlight real world use, safety of drug-eluting stents
6. Studies led by Rhode Island Hospital confirm safety and efficacy
7. Studies identify food sources of disease and drug resistance
8. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
9. Studies highlight need to monitor heart function in breast cancer patients
10. Studies examine physician disclosure of medical errors
11. Studies evaluating health effects of dental amalgam fillings in children confirm safety

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... ... February 08, 2016 , ... FileHold's ... organizations. DocuSyst provides a cloud hosted environment for FileHold software that is ... with various 3rd party applications using the FileHold web services API. DocuSyst also ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... share this important news! AHCC and the Home Health and Hospice ICD-10 Transition ... designee for official ICD coding guidance and clarifications, to address concerns over the ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 ... in honor of his birthday on February 10th. During this time, people can ... known by over 250,000 people from over 40 different countries as an “ordinary man ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... ... and Facial Plastics, has added Kybella® to his medical and surgical expertise. Technically ... newly approved FDA injectable medication used as a non-surgical alternative for reduction of ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... MEMPHIS, Tenn. , Feb. 8, 2016  A ... Hospital scientists has discovered details of how the ... cells triggers a particularly aggressive form of acute lymphoblastic ... cells, in which genetic mutations trigger overproduction of immature ... --> The discoveries of the malfunction underlying the ...
(Date:2/8/2016)... Feb. 8, 2016  As part of a major growth ... the appointment of Lori Chmura as President of ... in the industry, Chmura,s extensive experience in the medical device ... Dune Medical Devices. --> ... for leading all sales, marketing and operational functions in the ...
(Date:2/8/2016)... Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ... 2016, ended December 31, 2015, the Company achieved revenue of ... the same quarter in fiscal 2015. --> ... of fiscal year 2016 was $2,068,635, or $.03 per share, ... per share, in the Q2 of fiscal year 2015. Gross ...
Breaking Medicine Technology:
Cached News: